# US 2025/0144156 A1 · Microbial consortia and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144156 A1
- Document ID: US20250144156A1
- Status: Published application
- Kind: A1
- Application number: 18/915,109
- Filed: 2024-10-14
- Published: 2025-05-08
- Earliest claimed: 2023-10-12
- Applicants: The University of Chicago
- Inventors: Arjun S. Raman; Ana Rita Almeida de Oliveira; Seppe Kuehn
- Web page: https://patentgrep.com/patent/US20250144156A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/745: Bifidobacteria
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present document relates to microbial consortia and uses thereof.

## Claims

### Claim 1

A composition comprising a bacterial population comprising at least one bacterial strain, wherein the bacterial strain(s) is/are a Clostridium innocuum strain, a Clostridium symbiosum strain, a Collinsella aerofaciens strain, an Escherichia coli strain, a Bacteroides xylanisolvens strain, a Lacrimispora celerecrescens strain (or Clostridium celerecrescens strain), a Bacteroides caccae strain, a Blautia faecis strain, a Blautia obeum strain, a Clostridium scindens strain, a Bifidobacterium strain, a Megasphaera massiliensis strain, a Coprococcus comes strain, a Mitsuokella jalaludinii strain, a Blautia producta strain, or any combination thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the Clostridium innocuum strain comprises Clostridium innocuum strain MSK.7.7, the Clostridium symbiosum strain comprises Clostridium symbiosum strain MSK.7.21, the Collinsella aerofaciens strain comprises Collinsella aerofaciens strain MSK.1.10, the Escherichia coli strain comprises Escherichia coli strain MSK.19.28, the Bacteroides xylanisolvens strain comprises Bacteroides xylanisolvens strain MSK.20.34, the Lacrimispora celerecrescens strain comprises Lacrimispora celerecrescens strain MSK.15.50, the Bacteroides caccae strain comprises Bacteroides caccae strain MSK.18.53, the Blautia faecis strain comprises Blautia faecis strain MSK.17.74, the Blautia obeum strain comprises Blautia obeum strain MSK.13.37, the Clostridium scindens strain comprises Clostridium scindens strain MSK.5.24, the Bifidobacterium strain comprises Bipzdobacterium sp. MSK.13.1, the Megasphaera massiliensis strain comprises Megasphaera massiliensis strain MSK.20.21, the Coprococcus comes strain comprises Coprococcus comes strain MSK.17.59, the Mitsuokella jalaludinii strain comprises Mitsuokella jalaludinii strain MSK.21.47, and/or the Blautia producta strain comprises Blautia producta strain MSK.4.17.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the bacterial population is an isolated bacterial population.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the bacterial population comprises at least two different bacterial strains.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the bacterial population comprises at least 16 different bacterial strains.

### Claim at position 6

6-12. (canceled)

### Claim 13 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

### Claim at position 8

14-20. (canceled)

### Claim 21

A method for treating or prophylactically treating an infection in a patient, the method comprising administering a therapeutically effective amount of a composition to the patient, thereby treating or prophylactically treating infection, wherein the composition comprises a bacterial population comprising at least one bacterial strain, wherein the bacterial strain is a Clostridium innocuum strain, a Clostridium symbiosum strain, a Collinsella aerofaciens strain, an Escherichia coli strain, a Bacteroides xylanisolvens strain, a Lacrimispora celerecrescens strain, a Bacteroides caccae strain, a Blautia faecis strain, a Blautia obeum strain, a Clostridium scindens strain, a Bifidobacterium strain, a Megasphaera massiliensis strain, a Coprococcus comes strain, a Mitsuokella jalaludinii strain, a Blautia producta strain, or any combination thereof.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The method of claim 21, wherein the infection is caused by an Enterobacteriaceae sp.

### Claim 24 (depends on 21)

The method of claim 21, wherein the infection is caused by a drug resistant Enterobacteriaceae sp. or a multi-drug resistant Enterobacteriaceae sp.

### Claim 25 (depends on 21)

The method of claim 21, further comprising administering one or more antibiotics to the patient.

### Claim 26

A method for modulating one or more short chain fatty acids and/or one or more amino acids in a patient, the method comprising administering an effective amount of a composition to the patient, wherein the composition comprises a bacterial population comprising at least one bacterial strain, wherein the bacterial strain is a Clostridium innocuum strain, a Clostridium symbiosum strain, a Collinsella aerofaciens strain, an Escherichia coli strain, a Bacteroides xylanisolvens strain, a Lacrimispora celerecrescens strain, a Bacteroides caccae strain, a Blautia faecis strain, a Blautia obeum strain, a Clostridium scindens strain, a Bifidobacterium strain, a Megasphaera massiliensis strain, a Coprococcus comes strain, a Mitsuokella jalaludinii strain, a Blautia producta strain, or any combination thereof.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The method of claim 26, wherein the composition comprises at least two different bacteria strains.

### Claim 29 (depends on 26)

The method of claim 26, wherein the composition comprises at least 46 different bacteria strains.

### Claim 30 (depends on 26)

The method claim 26, wherein the composition comprises the bacterial strains of Block 1.

### Claim 31 (depends on 26)

The method of claim 26, wherein the composition comprises the bacterial strains of Block 2.

### Claim 32 (depends on 26)

The method of claim 26, wherein the composition comprises the bacterial strains of Block 3.

### Claim 33 (depends on 26)

The method of claim 26, wherein the composition comprises the bacterial strains of Block 4.

### Claim 34 (depends on 26)

The method of claim 26, wherein the composition comprises the bacterial strains of Block 5.

### Claim 35 (depends on 26)

The method of claim 26, wherein the composition comprises the bacterial strains of Block 1 and Block 5.
